News & Media

Pushing mRNA therapeutics for cancer, Cambridge startup nabs Series A to explore next-gen approach

Amgen-backed Kernal Biologics pops off with $25M for mRNA platform

Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology

The Vast Promise of mRNA Technology

Wall Street Journal

Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference

Startups set off new wave of mRNA therapeutics

Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19

You've met Moderna, BioNTech and CureVac. Now meet Kernal Bio, the startup working on mRNA 2.0.

Kernal mRNAs are heading to space!

Kernal is accepted to MassBio's MassConnect Program

Kernal Biologics wins Amgen's coveted Golden Ticket award for the second year in a row

Kernal Biologics receives Technology in Space Award from CASIS & Boeing through MassChallenge

Can mRNA disrupt the drug industry?